Your Good Partner in Biology Research

重組抗體

產(chǎn)品名稱 貨號(hào) 規(guī)格
CSF3R Recombinant Monoclonal Antibody CSB-RA860321MA1HU 100μl/50μl
SOST Recombinant Monoclonal Antibody CSB-RA858415MA1HU 100μl/50μl
GDF15 Recombinant Monoclonal Antibody CSB-RA859530MA1HU 100μl/50μl
ROR2 Recombinant Monoclonal Antibody CSB-RA932279MA1HU 100μl/50μl
TNFRSF4 Recombinant Monoclonal Antibody CSB-RA023981MA1HU 100μl/50μl
NT5E Recombinant Monoclonal Antibody CSB-RA723415MA1HU 100μl/50μl
CD37 Recombinant Monoclonal Antibody CSB-RA004928MA1HU 100μl/50μl
IL13RA1 Recombinant Monoclonal Antibody CSB-RA011591MA1HU 100μl/50μl
KDR Recombinant Monoclonal Antibody CSB-RA012145MA1HU 100μl/50μl
GREM1 Recombinant Monoclonal Antibody CSB-RA009892MA1HU 100μl/50μl
TLR4 Recombinant Monoclonal Antibody CSB-RA023603MA1HU 100μl/50μl
CD14 Recombinant Monoclonal Antibody CSB-RA004879MA1HU 100μl/50μl
SLC1A5 Recombinant Monoclonal Antibody CSB-RA620892MA1HU 100μl/50μl
FLT1 Recombinant Monoclonal Antibody CSB-RA008732MA1HU 100μl/50μl
CD3D Recombinant Monoclonal Antibody CSB-RA004930MA1HU 100μl/50μl
CD19 Recombinant Monoclonal Antibody CSB-RA004888MA2HU 100μl/50μl
KIT Recombinant Monoclonal Antibody CSB-RA012375MA1HU 100μl/50μl
LAG3 Recombinant Monoclonal Antibody CSB-RA012719MA1HU 100μl/50μl
CTLA4 Recombinant Monoclonal Antibody CSB-RA006163MA1HU 100μl/50μl
DXD Recombinant Monoclonal Antibody CSB-RA996977I1h 100μl/50μl

關(guān)于重組抗體

與傳統(tǒng)抗體相比,重組抗體的優(yōu)勢(shì)具體如下:

  • 更高的一致性和重復(fù)性

    因?yàn)橹亟M抗體是由一組獨(dú)特的基因發(fā)展而來的,所以抗體生產(chǎn)是可控且可靠的??梢员苊怆s交瘤細(xì)胞制備中的一些問題,如基因丟失、基因突變和細(xì)胞株漂移等。這使得抗體的批次間差異非常小,從而為您提供高度可重復(fù)的結(jié)果。

  • 更高的靈敏度和特異性

    利用重組技術(shù),更容易通過抗體工程提高抗體特異性和靈敏度。所需克隆的選擇過程發(fā)生在雜交瘤細(xì)胞和重組克隆階段,這使我們能夠選擇最優(yōu)的抗體質(zhì)量。

  • 易于擴(kuò)展

    隨著抗體基因的分離,與傳統(tǒng)單克隆技術(shù)相比,抗體表達(dá)能夠以任何規(guī)模在更短的時(shí)間內(nèi)進(jìn)行。這意味著我們可以在數(shù)周而非數(shù)月內(nèi)產(chǎn)生定制抗體。

  • 無動(dòng)物高通量生產(chǎn)

    一旦分離出產(chǎn)生抗體的基因,就可以實(shí)現(xiàn)無動(dòng)物體外生產(chǎn)。

重組抗體與傳統(tǒng)抗體的比較:

單克隆抗體 多克隆抗體 重組抗體
重復(fù)性 高;批次間差異小 更高;高純度,批次間差異更小
特異性 強(qiáng) 更強(qiáng)
生產(chǎn)周期 4到6個(gè)月的開發(fā);4到6周的生產(chǎn) 2到3個(gè)月的開發(fā)和生產(chǎn) 4個(gè)月的開發(fā);1到6周的生產(chǎn)
同型亞基轉(zhuǎn)換 困難 困難 方便
表達(dá)系統(tǒng) 小鼠腹水法和體外方法 通常在哺乳動(dòng)物細(xì)胞(如兔) 通常在哺乳動(dòng)物細(xì)胞系中,也可在特殊工程細(xì)胞系中表達(dá),如酵母、細(xì)菌、昆蟲和轉(zhuǎn)基因植物
成本 生產(chǎn)成本較高;需要更專業(yè)的人員操作 成本相對(duì)較低 需要技術(shù)專長(zhǎng)和較大的時(shí)間和金錢投入進(jìn)行生產(chǎn)
人類免疫應(yīng)答 無法避免 無法避免 可避免

更多重組抗體概述點(diǎn)擊查看>>

引用文獻(xiàn)

S Antibody referenced in "A magneto-optical biochip for rapid assay based on the Cotton–Mouton effect of γ-Fe2O3@ Au core/shell nanoparticles", Journal of nanobiotechnology, 2021.

SARS-CoV-2 Spike RBD Nanobody referenced in "Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2", Bioorganic & Medicinal Chemistry, 2021.

HIF1A Antibody, CASP3 Antibody referenced in "PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia", Cancer cell international, 2021.

Phospho-ERN1 (S724) Antibody referenced in "The ER stress sensor inositol-requiring enzyme 1α in Kupffer cells promotes hepatic ischemia-reperfusion injury", Journal of Biological Chemistry, 2021.

CDK4 Antibody and CDK6 Antibody referenced in "Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells Via Forkhead Box M1 Suppression", Journal of Cancer, 2021.

BIRC5 Antibody referenced in "LTBP4 Inhibits the Proliferation and Metastasis in Melanoma by Activating Hippo-YAP Signaling", Research Square, 2020.

查看更多 >>